Nikolaus R Mcfarland

List of Publications by Year
in descending order

79 papers	5,807 citations	126907 33 h-index	76900 74 g-index
79 all docs	79 docs citations	79 times ranked	7493 citing authors

#	Article	IF	Citations
1	Diffusion Magnetic Resonance Imaging Detects Progression in <scp>Parkinson's</scp> Disease: A Placeboâ€Controlled Trial of Rasagiline. Movement Disorders, 2022, 37, 325-333.	3.9	7
2	Development and Validation of Automated <scp>Magnetic Resonance</scp> Parkinsonism Index 2.0 to Distinguish <scp>Progressive Supranuclear Palsyâ€Parkinsonism</scp> From <scp>Parkinson's Disease</scp>. Movement Disorders, 2022, 37, 1272-1281.	3.9	17
3	Advanced diffusion imaging to track progression in Parkinsonâ€™s disease, multiple system atrophy, and progressive supranuclear palsy. NeuroImage: Clinical, 2022, 34, 103022.	2.7	12
4	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. Movement Disorders, 2021, 36, 681-689.	3.9	22
5	Statistically Defined Parkinsonâ€™s Disease Executive and Memory Cognitive Phenotypes: Demographic, Behavioral, and Structural Neuroimaging Comparisons. Journal of Parkinson's Disease, 2021, 11, 283-297.	2.8	8
6	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 182-192.	10.2	74
7	The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. Npj Parkinson's Disease, 2021, 7, 16.	5.3	10
8	Robust Î±-synuclein pathology in select brainstem neuronal populations is a potential instigator of multiple system atrophy. Acta Neuropathologica Communications, 2021, 9, 80.	5.2	11
9	Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. Frontiers in Neurology, 2021, 12, 694872.	2.4	29
10	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	3.9	37
11	Mild cognitive impairment and dementia in motor manifest Huntington's disease: Classification and prevalence. Journal of the Neurological Sciences, 2020, 408, 116523.	0.6	33
12	Earlyâ€Motor Phenotype Relates to Neuropsychiatric and Cognitive Disorders in Huntington's Disease. Movement Disorders, 2020, 35, 781-788.	3.9	12
13	Current Management and Emerging Therapies in Multiple System Atrophy. Neurotherapeutics, 2020, 17, 1582-1602.	4.4	11
14	Introducing a Supportive Care Team for Advance Directive Education in a Neurological and Neurosurgical Patient Population. Journal of Patient Experience, 2020, 7, 1286-1293.	0.9	2
15	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. Movement Disorders, 2020, 35, 976-983.	3.9	38
16	Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism. Movement Disorders, 2020, 35, 1388-1395.	3.9	15
17	Neurite orientation dispersion and density imaging (NODDI) and freeâ€water imaging in Parkinsonism. Human Brain Mapping, 2019, 40, 5094-5107.	3.6	71
18	Development of a transcallosal tractography template and its application to dementia. NeuroImage, 2019, 200, 302-312.	4.2	28

#	Article	IF	Citations
19	A turn for the worse: Turning performance in Parkinson's disease and Essential tremor. Clinical Biomechanics, 2019, 70, 245-248.	1.2	6
20	Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. The Lancet Digital Health, 2019, 1, e222-e231.	12.3	73
21	Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurology, The, 2019, 18, 549-558.	10.2	108
22	Dissecting Î±-synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis. Laboratory Investigation, 2019, 99, 982-992.	3.7	15
23	Recognizing and treating atypical Parkinson disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 301-320.	1.8	10
24	Depressive Symptoms are Frequent in Atypical Parkinsonian Disorders. Movement Disorders Clinical Practice, 2017, 4, 191-197.	1.5	24
25	Recognizing Atypical Parkinsonisms: â€œRed Flagsâ€•and Therapeutic Approaches. Seminars in Neurology, 2017, 37, 215-227.	1.4	30
26	A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology, 2017, 88, 152-159.	1.1	104
27	Parkinson Disease and Autoimmune Disordersâ€"What Can We Learn From Genome-wide Pleiotropy?. JAMA Neurology, 2017, 74, 769.	9.0	2
28	Functional activity of the sensorimotor cortex and cerebellum relates to cervical dystonia symptoms. Human Brain Mapping, 2017, 38, 4563-4573.	3.6	49
29	Progression marker of Parkinsonâ€™s disease: a 4-year multi-site imaging study. Brain, 2017, 140, 2183-2192.	7.6	139
30	Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study. Movement Disorders, 2017, 32, 1457-1464.	3.9	60
31	Striatal and Hippocampal Atrophy in Idiopathic Parkinsonâ€™s Disease Patients without Dementia: A Morphometric Analysis. Frontiers in Neurology, 2017, 8, 139.	2.4	32
32	The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome. PLoS ONE, 2017, 12, e0184262.	2.5	15
33	The Exam Starts in the Hallway: Movement Disorders in Geriatric Psychiatry. American Journal of Geriatric Psychiatry, 2016, 24, S10-S11.	1.2	0
34	Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes. Neurology, 2016, 87, 709-717.	1.1	45
35	Freeâ€water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAOâ€B inhibitor. Human Brain Mapping, 2016, 37, 2894-2903.	3.6	31
36	The relationship between balance confidence and control in individuals with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 26, 24-28.	2.2	22

#	Article	IF	Citations
37	Free-water imaging in Parkinsonâ€™s disease and atypical parkinsonism. Brain, 2016, 139, 495-508.	7.6	165
38	Diagnostic Approach to Atypical Parkinsonian Syndromes. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 1117-1142.	0.8	60
39	Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice. Molecular Neurodegeneration, 2015, 10, 25.	10.8	47
40	Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease. Movement Disorders, 2015, 30, 1248-1258.	3.9	52
41	Weight Loss and Impact on Quality of Life in Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0124541.	2.5	54
42	Unexpected Dual Task Benefits on Cycling in Parkinson Disease and Healthy Adults: A Neuro-Behavioral Model. PLoS ONE, 2015, 10, e0125470.	2.5	20
43	Discriminating features of gait performance in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2015, 21, 888-893.	2.2	21
44	The Exam Starts in the Hallway: Movement Disorders in Geriatric Psychiatry. American Journal of Geriatric Psychiatry, 2015, 23, S21-S22.	1.2	0
45	Repetitive finger movement performance differs among Parkinsonâ€™s disease, Progressive Supranuclear Palsy, and spinocerebellar ataxia. Journal of Clinical Movement Disorders, 2015, 2, 6.	2.2	7
46	Global attentional neglect of segmented lines in Parkinsonâ€™s disease. Neurocase, 2015, 21, 501-508.	0.6	5
47	Abnormal tactile pressure perception in Parkinsonâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2015, 37, 808-815.	1.3	3
48	Distinct functional and macrostructural brain changes in <scp>P</scp>arkinson's disease and multiple system atrophy. Human Brain Mapping, 2015, 36, 1165-1179.	3.6	51
49	Chronic Treatment with Novel Small Molecule Hsp90 Inhibitors Rescues Striatal Dopamine Levels but Not Î±-Synuclein-Induced Neuronal Cell Loss. PLoS ONE, 2014, 9, e86048.	2.5	35
50	Driving Errors in Parkinsonâ€™s Disease: Moving Closer to Predicting On-Road Outcomes. American Journal of Occupational Therapy, 2014, 68, 77-85.	0.3	27
51	Defining the Clinically Meaningful Difference in Gait Speed in Persons With Parkinson Disease. Journal of Neurologic Physical Therapy, 2014, 38, 233-238.	1.4	113
52	MRI Reveals Brain Abnormalities in Drug-Naive Parkinsonâ€™s Disease. Exercise and Sport Sciences Reviews, 2014, 42, 12-22.	3.0	13
53	The Exam Starts in the Hallway: Movement Disorders in Geriatric Psychiatry. American Journal of Geriatric Psychiatry, 2014, 22, S32-S33.	1.2	0
54	An Eight-Year Clinic Experience with Clozapine Use in a Parkinsonâ€™s Disease Clinic Setting. PLoS ONE, 2014, 9, e91545.	2.5	41

#	Article	IF	Citations
55	The â€œBrittle Responseâ€• to Parkinsonâ€™s Disease Medications: Characterization and Response to Deep Brain Stimulation. PLoS ONE, 2014, 9, e94856.	2.5	19
56	Efficient determination of purine metabolites in brain tissue and serum by highâ€performance liquid chromatography with electrochemical and UV detection. Biomedical Chromatography, 2013, 27, 122-129.	1.7	22
57	Variability in clinical phenotypes of heterozygous and homozygous cases ofParkin-related Parkinson's disease. International Journal of Neuroscience, 2013, 123, 847-849.	1.6	4
58	Postural/Gait and Cognitive Function as Predictors of Driving Performance in Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 153-160.	2.8	14
59	Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathologica Communications, 2013, 1, 6.	5.2	49
60	Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinsonâ€™s disease. Journal of Neurology, 2013, 260, 521-527.	3.6	33
61	Advancing research towards novel therapeutic approaches. Nature Reviews Neurology, 2013, 9, 70-71.	10.1	0
62	Anti-Tau Antibodies: Hitting the Target. Neuron, 2013, 80, 254-256.	8.1	16
63	Driving Performance and Behaviors: A Comparison of Gender Differences in Parkinson's Disease. Traffic Injury Prevention, 2013, 14, 340-345.	1.4	13
64	Postmortem Brain Levels of Urate and Precursors in Parkinson's Disease and Related Disorders. Neurodegenerative Diseases, 2013, 12, 189-198.	1.4	57
65	Deep brain stimulation response in pathologically confirmed cases of multiple system atrophy. Parkinsonism and Related Disorders, 2012, 18, 86-88.	2.2	16
66	Are Selective Serotonin Reuptake Inhibitors Associated With Greater Apathy in Parkinsonâ€™s Disease?. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, 326-330.	1.8	54
67	Neurogenic potential of progenitor cells isolated from postmortem human Parkinsonian brains. Brain Research, 2012, 1464, 61-72.	2.2	34
68	Interferon-Î³ induces progressive nigrostriatal degeneration and basal ganglia calcification. Nature Neuroscience, 2011, 14, 694-696.	14.8	67
69	Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. Journal of Neurochemistry, 2009, 109, 838-845.	3.9	91
70	Î±-Synuclein S129 Phosphorylation Mutants Do Not Alter Nigrostriatal Toxicity in a Rat Model of Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 515-524.	1.7	111
71	Improvement with corticosteroids and azathioprine in GAD65-associated cerebellar ataxia. Neurology, 2006, 67, 1308-1309.	1.1	17
72	Thalamic Relay Nuclei of the Basal Ganglia Form Both Reciprocal and Nonreciprocal Cortical Connections, Linking Multiple Frontal Cortical Areas. Journal of Neuroscience, 2002, 22, 8117-8132.	3.6	413

#	Article	IF	Citations
73	The Place of the Thalamus in Frontal Cortical-Basal Ganglia Circuits. Neuroscientist, 2001, 7, 315-324.	3.5	163
74	Organization of thalamostriatal terminals from the ventral motor nuclei in the macaque. Journal of Comparative Neurology, 2001, 429, 321-336.	1.6	94
75	Convergent Inputs from Thalamic Motor Nuclei and Frontal Cortical Areas to the Dorsal Striatum in the Primate. Journal of Neuroscience, 2000, 20, 3798-3813.	3.6	213
76	Striatonigrostriatal Pathways in Primates Form an Ascending Spiral from the Shell to the Dorsolateral Striatum. Journal of Neuroscience, 2000, 20, 2369-2382.	3.6	1,753
77	The Concept of the Ventral Striatum in Nonhuman Primates. Annals of the New York Academy of Sciences, 1999, 877, 33-48.	3.8	210
78	Insular Cortical Projections to Functional Regions of the Striatum Correlate with Cortical Cytoarchitectonic Organization in the Primate. Journal of Neuroscience, 1997, 17, 9686-9705.	3.6	303
79	Organization of thalamic projections to the ventral striatum in the primate. Journal of Comparative Neurology, 1995, 354, 127-149.	1.6	125